IL6 and head and neck squamous cell carcinoma: We recently showed that tumor explants retain both myCAF and iCAF subpopulations in HNSCC and are suitable for evaluating drugs targeting the tumor microenvironment.[53] We exposed these tumor explants to either paclitaxel or DMSO (control), and subsequently probed for PDPN (pan‐CAF marker in HNSCC[31]) and either α‐SMA (ACTA2) for myCAFs or IL‐6 for IL‐iCAFs.